Open AccessJournal Article
Collaborative overview of randomized trials of antiplatelet therapy .1. prevention of death, myocardial-infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
R Altman,L Carreras,R Diaz,E Figueroa,E Paolasso,J C Parodi,J F Cade,G Donnan,M J Eadie,T P Gavaghan,E F Osullivan,D Parkin,Renny Jtg.,C Silagy,H Vinazzer,F Zekert,H Adriaensen,J M Bertrandhardy,M Bran,J L David,J Dricot,E Lavennepardonge,R Limet,A Lowenthal,M Moriau,S Schapira,P Smets,J Symoens,R Verhaeghe,Marc Verstraete,A Atallah,H Barnett,R Batista,J Blakely,J A Cairns,R Cote,J Crouch,G Evans,J M Findlay,M Gent,Y Langlois,J Leclerc,J Norris,G F Pineo,P J Powers,R Roberts,L Schwartz,J Sicurella,W Taylor,P Theroux,Alexander G.G. Turpie,R D Weisel,J Cui,L Liu,J Pirk,C Bay,G Boysen,J B Knudsen,P Petersen,P S Sorensen,H K Tonnesen,P T Harjola,J C Arcan,B Balkau,J Blanchard,J P Boissel,B Boneu,M G Bousser,M Brochier,M Cloarec,G Cribier,M Dechavanne,P Drouin,E Eschwege,B Guiraudchaumeil,R Hugonot,A Leizorovicz,Y Loria,L Michat,J Mirouze,E Panak,J Pasteyer,A Rascol,L Revol,Maarten Van Roy,J Selles,G Slama,C Starkman,M Teule,N Thibult,M Verry,F W Albert,K Andrassy,K Breddin,R Eckel,A Encke,J Frohlich,B Hartung,H W Heiss,H Hess,B Hofling,D Krause,G Latta,H Linke,D Loew,R Lorenz,K Middleton,G Novak,M Oldendorf,N Pfluger,D Raithel,R Reuter,G Schettler,J Schnitker,W Schoop,H Stiegler,K Uberla,G Vogel,M Weber,I Welbers,E Zeitler,G Arapakis,T Chan,C K Mok,R Szabo,N P Misra,K Reddy,G A Fitzgerald,A Apollonio,F Balsano,A Basellini,L Candelise,Mariella Catalano,N Ciavarella,G Ciuffetti,S Coccheri,M Cortellaro,G Corvi,V Coto,Giovanni Davì,R Decaterina,T Diperri,C Fieschi,R Gentile,L Gregoratti,Paolo Gresele,M Lavezzari,A Libretti,B Magnani,G.G. Nenci,G Pagano,Carlo Patrono,L Pedrini,M Pini,Paolo Prandoni,F Romeo,F Rovelli,G Rudelli,G Ruvolo,G P Signorini,G Tognoni,Francesco Violi,T Fujimori,M Kageyama,T Katsumura,S Kitamura,K Maeda,A Suzuki,H Tohgi,S Uchiyama,H Utsumi,A M Garcia,A Algra,Denottolander Gjh.,Kupper Ajf.,J Vangijn,H Hart,L J Kappelle,P J Koudstaal,T Lemmens,J Lodder,M Pannebakker,P W Serruys,A Vandenbelt,J Vandermeer,A B Vandervijgh,Verheugt Fwa.,G Veth,J Dale,K A Johannessen,E Thaulow,P Popescu,N Tiberiu,Aznar Jrd.,E Esmatjes,P Guiteras,J Lasierra,P Lopeztrigo,A Oriol,L Pomar,E Rocha,F D Sanchez,J Sanchorieger,G Sanz,Berglund Ulf.,C Blomstrand,M Boberg,M Britton,C E Elwin,C Helmers,J Holm,L Janzon,S Juulmoller,H Mulec,J E Olsson,S Persson,G Rasmanis,A Rosen,K Samuelsson,J Soreff,N Wahlgren,L Wallentin,H R Baur,M Bokslag,A Bollinger,B Meier,M Pfisterer,C Sitthiamorn,E J Acheson,P Appleby,A W Asscher,A Aukland,Colin Baigent,S Bala,A H Barnett,P Bell,S Bews,Born Gvr.,J P Branagan,N Brooks,M J Brown,N L Browse,R Capildeo,M Carmalt,A E Carter,I Chalmers,Mike Clarke,Robert Clarke,Clyne Cac.,Rory Collins,Cooke,G Coutts,D H Cove,P S Crowther,W F Cuthbertson,D Debono,C Dickerson,J P Dickinson,Richard Doll,J A Dormandy,D Dunbabin,S Ell,P Elphinstone,P Elwood,V Englishby,B Farrell,C Fiskerstrand,M Flather,T Foley,T Foulds,K M Fox,Peter Franks,H Fraser,T Gardecki,M Gawel,A E Gent,A H Gershlick,J Godwin,M Goldman,C Gray,D Gray,Richard Gray,H Handoll,G Hankey,Harrison Mjg.,N Henderson,S Heptinstall,S F Hobbiger,E W Jones,Jones Nag.,S Jost,D Julian,J Kellett,R C Kester,G Lowe,J Mackenzie,C N McCollum,G Mead,T W Meade,D Mendelow,J C Miller,G K Morris,C Nichol,M Noble,Obrien,M Ogier,Sarah Parish,M J Parry,Richard Peto,Janet T. Powell,P Pozzilli,N Qizilbash,A Rahman,S M Rajah,D H Richards,S Richards,Ruth M. Ripley,V C Roberts,F C Rose,Russell Rwr.,P C Rubin,C V Ruckley,Peter Sandercock,Shaw Mdm.,K M Shaw,J H Shelley,J Slattery,Peter Sleight,S J Smith,P Stewartlong,P M Sweetnam,Tansey Mjb.,H Tindall,J Turney,H M Tyler,N C Varey,M P Vessey,M G Walker,M A Walker,C P Warlow,R G Wilcox,H Willems,E H Wood,E Wynjones,H P Adams,B Barton,R F Bedford,B L Bick,S Bingham,B G Brown,T Bryant,J Buring,C F Cabot,P Canner,J Chesebro,O D Chrisman,G P Clagett,J A Colwell,M Dyken,D Ellis,W S Fields,C Furberg,V Fuster,S Goldman,J Granett,R M Green,D Green,R Hardy,L A Harker,W H Harris,R G Hart,W K Hass,Charles H. Hennekens,D Hill,M Hume,M C Igloe,G Johnson,S Jonas,G Knatterud,T R Kohler,N J Lembo,D Lewis,E Lockhart,P Majerus,Mcenany,R Mckenna,J L Mehta,J S Meyer,B Molony,T Moritz,D M Nicoloff,G Nycz,H Ono,G A Pantely,S J Phillips,Paul M. Ridker,J T Robertson,R Rothbart,E W Salzman,R D Sautter,R C Schlant,J A Schoenberger,M V Sengekontacket,G Sharma,P Steele,K P Steinnagel,J Stratton,J M Sullivan,G Timmis,J F Toole,Walker,S Weisman,C W White,M Wirecki,D Wombolt,R Wong,Salim Yusuf,K Zadina,D Zucker +418 more
TLDR
There was no appreciable evidence that either a higher aspirin dose or any other antiplatelet regimen was more effective than medium dose aspirin in preventing vascular events, so in each of the four main high risk categories overall mortality was significantly reduced.Abstract:
Abstract Objective: To determine the effects of “prolonged” antiplatelet therapy (that is, given for one month or more) on “vascular events” (non-fatal myocardial infarctions, non-fatal strokes, or vascular deaths) in various categories of patients. Design: Overviews of 145 randomised trials of “prolonged” antiplatelet therapy versus control and 29 randomised comparisons between such antiplatelet regimens. Setting: Randomised trials that could have been available by March 1990. Subjects: Trials of antiplatelet therapy versus control included about 70 000 “high risk” patients (that is, with some vascular disease or other condition implying an increased risk of occlusive vascular disease) and 30 000 “low risk” subjects from the general population. Direct comparisons of different antiplatelet regimens involved about 10 000 high risk patients. Results: In each of four main high risk categories of patients antiplatelet therapy was definitely protective. The percentages of patients suffering a vascular event among those allocated antiplatelet therapy versus appropriately adjusted control percentages (and mean scheduled treatment durations and net absolute benefits) were: (a) among about 20 000 patients with acute myocardial infarction, 10% antiplatelet therapy v 14% control (one month benefit about 40 vascular events avoided per 1000 patients treated (2P< 0.00001)); (b) among about 20 000 patients with a past history of myocardial infarction, 13% antiplatelet therapy v 17% control (two year benefit about 40/1000 (2P<0.00001)); (c) among about 10 000 patients with a past history of stroke or transient ischaemic attack, 18% antiplatelet therapy v 22% control (three year benefit about 40/1000 (2P<0.00001)); (d) among about 20 000 patients with some other relevant medical history (unstable angina, stable angina, vascular surgery, angioplasty, atrial fibrillation, valvular disease, peripheral vascular disease, etc), 9% v 14% in 4000 patients with unstable angina (six month benefit about 50/1000 (2P<0.00001)) and 6% v 8% in 16 000 other high risk patients (one year benefit about 20/1000 (2P<0.00001)). Reductions in vascular events were about one quarter in each of these four main categories and were separately statistically significant in middle age and old age, in men and women, in hypertensive and normotensive patients, and in diabetic and non: diabetic patients. Taking all high risk patients together showed reductions of about one third in non-fatal myocardial infarction, about one third in non-fatal stroke, and about one sixth in vascular death (each 2P<0.00001). There was no evidence that non-vascular deaths were increased, so in each of the four main high risk categories overall mortality was significantly reduced. The most widely tested antiplatelet regimen was “medium dose” (75-325 mg/day) aspirin. Doses throughout this range seemed similarly effective (although in an acute emergency it might be prudent to use an initial dose of 160-325 mg rather than about 75 mg). There was no appreciable evidence that either a higher aspirin dose or any other antiplatelet regimen was more effective than medium dose aspirin in preventing vascular events. The optimal duration of treatment for patients with a past history of myocardial infarction, stroke, or transient ischaemic attack could not be determined directly because most trials lasted only one, two, or three years (average about two years). Nevertheless, there was significant (2P<0.00001) further benefit between the end of year 1 and the end of year 3, suggesting that longer treatment might well be more effective. Among low risk recipients of “primary prevention” a significant reduction of one third in non: fatal myocardial infarction was, however, accompanied by a non-significant increase in stroke. Furthermore, the absolute reduction in vascular events was much smaller than for high risk patients despite a much longer treatment period (4.4% antiplatelet therapy v 4.8% control; five year benefit only about four per 1000 patients treated) and was not significant (2P=0.09). Conclusions: Among a much wider range of patients at high risk of occlusive vascular disease than is currently treated routinely, some years of antiplatelet therapy - with aspirin 75-325 mg/day or some other antiplatelet regimen (provided there are no contraindications) - offers worthwhile protection against myocardial infarction, stroke, and death. Significant benefit is evident not only among patients with unstable angina, suspected acute myocardial infarction, or a past history of myocardial infarction, stroke, or transient ischaemic attack, but also among many other categories of high risk patients (such as those having vascular procedures and those with stable angina or peripheral vascular disease). There is as yet, however, no clear evidence on the balance of risks and benefits of antiplatelet therapy in primary prevention among low risk subjects.read more
Citations
More filters
Journal ArticleDOI
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)
Massimo Piepoli,Arno W. Hoes,Stefan Agewall,Christian Albus,Carlos Brotons,Alberico L. Catapano,Marie Therese Cooney,Ugo Corrà,Bernard Cosyns,Christi Deaton,Ian D. Graham,Michael Stephen Hall,FD Richard Hobbs,Maja Lisa Løchen,Herbert Löllgen,Pedro Marques-Vidal,Joep Perk,Eva Prescott,Josep Redon,Dimitrios J. Richter,Naveed Sattar,Y.M. Smulders,Monica Tiberi,H. Bart van der Worp,Ineke van Dis,W M Monique Verschuren +25 more
TL;DR: In this paper, a randomized clinical trial was conducted to evaluate the effect of preterax and Diamicron Modified Release Controlled Evaluation (MDE) on the risk of stroke.
Journal ArticleDOI
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
Lars Norgren,William R. Hiatt,John A. Dormandy,Mark R. Nehler,Kenneth A. Harris,F. G. R. Fowkes +5 more
TL;DR: The goals of this new consensus are to provide an abbreviated document to focus on key aspects of diagnosis and management, and to update the information based on new publications and the newer guidelines, but not to add an extensive list of references.
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina)
Eugene Braunwald,Elliott M. Antman,John W. Beasley,Robert M. Califf,Melvin D. Cheitlin,Judith S. Hochman,Robert H. Jones,Dean J. Kereiakes,Joel Kupersmith,Thomas N. Levin,Carl J. Pepine,John W. Schaeffer,Earl E. Smith,David E Steward,Pierre Theroux,Raymond J. Gibbons,Joseph S. Alpert,David P. Faxon,Valentin Fuster,Gabriel Gregoratos,Loren F. Hiratzka,Alice K. Jacobs,Sidney C. Smith +22 more
TL;DR: The present guidelines supersede the 1994 guidelines and summarize both the evidence and expert opinion and provide final recommendations for both patient evaluation and therapy.
Journal ArticleDOI
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld,David M. Brown,Jeffrey S. Heier,David S. Boyer,Peter K. Kaiser,Carol Chung,Robert Y. Kim +6 more
TL;DR: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration.
References
More filters
Journal ArticleDOI
Aspirin use and reduced risk of fatal colon cancer
TL;DR: Regular aspirin use at low doses may reduce the risk of fatal colon cancer in people who used aspirin 16 or more times per month for at least one year.
Journal ArticleDOI
Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.
H D Lewis,J W Davis,Donald G. Archibald,W E Steinke,T C Smitherman,J E Doherty rd,H W Schnaper,M M LeWinter,E Linares,J M Pouget,S C Sabharwal,E Chesler,H DeMots +12 more
TL;DR: The data show that aspirin has a protective effect against acute myocardial infarction in men with unstable angina, and they suggest a similar effect on mortality.
Journal Article
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
Mg Ceravolo,Leandro Provinciali +1 more
Journal ArticleDOI
Stroke Prevention in Atrial Fibrillation Study. Final results.
TL;DR: Aspirin and warfarin are both effective in reducing ischemic stroke and systemic embolism in patients with atrial fibrillation and patients with nonrheumatic atrialfibrillation who can safely take either aspirin or warfarIn should receive prophylactic antithrombotic therapy to reduce the risk of stroke.
Journal ArticleDOI
Randomised trial of prophylactic daily aspirin in British male doctors
Richard Peto,Richard Gray,Rory Collins,Keith Wheatley,Charles H. Hennekens,K Jamrozik,Charles Warlow,B Hafner,E Thompson,S Norton +9 more
TL;DR: A six year randomised trial was conducted among 5139 apparently healthy male doctors to see whether 500 mg aspirin daily would reduce the incidence of and mortality from stroke, myocardial infarction, or other vascular conditions.